
Signal Alert: Startup Seeks Community Funders for AAV Immuno-Gene Therapy
Nicole K. Paulk, PhD, CEO, founder, and president, Siren Biotechnology A startup committed to developing the world’s first universal adeno-associated viral (AAV) vector-based gene therapy for solid tumor cancers, with an initial focus on brain cancers, is …